Please Wait
Applying Filters...

Annual Sales of Exenatide reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Bydureon

02 2Bydureon

03 6Byetta

04 2Byetta

PharmaCompass
Left Arrow
Right Arrow

01

Brand Name : Byetta

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Byetta

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 68

2019 Revenue in Millions : 110

Growth (%) : -38

blank

02

Brand Name : Bydureon

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Bydureon

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 448

2019 Revenue in Millions : 549

Growth (%) : -18

blank

03

Brand Name : Bydureon

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Bydureon

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 385

2020 Revenue in Millions : 448

Growth (%) : -14

blank

04

Brand Name : Byetta

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Byetta

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 55

2020 Revenue in Millions : 68

Growth (%) : -19

blank

05

Brand Name : Bydureon

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Bydureon

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 280

2021 Revenue in Millions : 385

Growth (%) : -27

blank

06

Brand Name : Bydureon

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Bydureon

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 163

2022 Revenue in Millions : 280

Growth (%) : -42

blank

07

Brand Name : Bydureon

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Bydureon

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2015 Revenue in Millions : 440

2014 Revenue in Millions : 580

Growth (%) : 32%

blank

08

Brand Name : Byetta

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Byetta

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2015 Revenue in Millions : 327

2014 Revenue in Millions : 316

Growth (%) : -3%

blank

09

Brand Name : Byetta

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Byetta

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2017 Revenue in Millions : 176

2016 Revenue in Millions : 254

Growth (%) : -31

blank

10

Brand Name : Bydureon

Exenatide

arrow
Saudi International Expo
Not Confirmed

Brand Name : Bydureon

arrow
Saudi International Expo
Not Confirmed

Exenatide

Main Therapeutic Indication : Diabetes

Currency : USD

2017 Revenue in Millions : 574

2016 Revenue in Millions : 578

Growth (%) : -1

blank